You are here

ASCO 2017: Options for NSCLC Patients Progressing After EGFR Treatment

Dr. Thomas Stinchcombe, Division of Medical Oncology, Duke University

Filmed by PracticeUpdate with permission for inclusion on Milestones in NSCLC. More information and additional ASCO coverage can be found at http://www.practiceupdate.com.

 

SUMMARY

At the 2017 ASCO annual meeting, Dr. Thomas Stinchcombe, Division of Medical Oncology, Duke University, described how ablative therapy and reinitiation of erlotinib can be used in EGFR-mutant non-small cell lung cancer (NSCLC) with CNS or limited systemic disease progression. Prospective data presented by Jared Weiss, University of North Carolina, showed that this is associated with a progression-free survival of 5-6 months. He commented, “This is a viable strategy as we try and extend the life of each line of our therapies“.

For T790M-positive NSCLC patients with disseminated disease or multiple progressing spots, osimertinib is the standard of care. This should be the preferred approach too in a subset of patients for whom no biopsy can be obtained or who are T790M-negative.

Dr. Stinchcombe reported a phase II trial evaluating T-DM1 in patients with HER2-positive metastatic NSCLC previously treated with chemotherapy. 34 % of the patients entered into two cohorts based on an immunohistochemical status (IHC) of 2+ or 3+ and received T-DM1. The response rate was 0% for patients testing IHC 2+ and 20% for those testing IHC 3+. “This is very good in pretreated patients. But additional research is needed to identify the patients mostly likely to benefit from T-DM1”, commented Dr. Stinchcombe. He correlated his study with the basket trial presented by Dr. Lee of the Memorial Sloan Kettering, but with patients selected on the basis of HER2 mutation. The response rate was about 44% - these are about 3% or 4% of adenocarcinomas. “That is very impressive“, concluded Thomas Stinchcombe. “I think that both these trials suggest that we should investigate this agent further in biomarker selected lung cancer patients”.

Stay informed

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Society partner

Made possible by an educational grant from

Please note that Lilly Oncology has no editorial control over the content of this Resource Centre. The Resource Centre and all content therein has been subjected to an independent editorial review.

A few pearls from ELCC 2017

5-8 May 2017, Geneva

by Stefan Zimmermann

A high-level forum where critical issues we face as thoracic oncologists are discussed, and cutting-edge new research is presented. 

Perspectives in Lung Cancer 2017

How I optimize treatment for my NSCLC patients with advanced and aggressive disease


Now available: Webcast on demand


 

Interactive Case Reports

Read more about recent cases from the Journal of Thoracic Oncology. Test your knowledge and answer the questions following the case to get immediate feedback.